Want to see ERAS full AI Analyst Report?
ERAS Stock Chart & Stats
$19.49
-$0.24(-1.26%)
At close: 4:00 PM EDT
$19.49
-$0.24(-1.26%)
Day’s Range― - ―
52-Week Range$1.41 - $24.28
Previous Close$19.1
Volume3.53M
Average Volume (3M)3.43M
Market Cap
$5.73B
Enterprise Value$5.48K
Total Cash (Recent Filing)$268.74M
Total Debt (Recent Filing)$44.71M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Nov 11, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.95
Shares Outstanding349,762,020
10 Day Avg. Volume3,950,712
30 Day Avg. Volume3,430,354
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-11.03
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.13Price Target Upside23.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.96
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ERAS-0015 Clinical ActivityEarly response activity in a difficult-to-treat, genetically defined cancer supports the pipeline’s commercial potential. The generally tolerable safety profile and absence of dose-limiting toxicities may also facilitate continued development and combination studies.
Regulatory DevelopmentFast Track provides opportunities for more frequent FDA interaction and may support a more efficient development and review process. Although it does not guarantee approval, the designation reinforces regulatory recognition of an unmet medical need.
R&D LeadershipAdding an experienced oncology leader can strengthen clinical strategy, trial execution and scientific decision-making as Erasca advances multiple RAS/MAPK programs. This is important for converting promising early data into registration-enabling studies.
Bears Say
Pre-Revenue Business ModelWith no commercial revenue, Erasca remains dependent on external financing, partnerships or future product approvals to fund operations. This leaves the business exposed to development delays and means pipeline success is essential for establishing a durable revenue base.
Widening LossesLarge and worsening losses indicate that development spending currently far exceeds any operating income. Continued losses can erode equity and increase the amount of capital required before commercialization, particularly if pivotal trials expand as planned.
Persistent Cash BurnNegative operating and free cash flow show that the company cannot yet self-fund its research and clinical programs. Ongoing reliance on capital markets creates refinancing and dilution risk if development timelines lengthen or funding conditions become less favorable.
Erasca News
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.41 and its highest was $24.28 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $5.73B.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Nov 11, 2026 which is in 68 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.111 by -$0.029.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.13.
How many shares outstanding does Erasca have?
Erasca has 349,762,020 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.111. Following the earnings report the stock price went up 0.766%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Erasca Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.13 (23.78% Upside)
$24.13 (23.78% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 74.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1037.06%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Erasca
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
ERAS Stock 12 Month Forecast
Average Price Target
$24.13
▲(23.78% Upside)
Technical Analysis
Arcturus Therapeutics
―
Arvinas Holding Company
―
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
9.65% Insiders
11.34% Mutual Funds
48.38% Other Institutional Investors
18.76% Public Companies and
Individual Investors